公开(公告)号：US20160346308A1

公开(公告)日：2016-12-01

申请号：US15234291

申请日：2016-08-11

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/7056 ,  A61K9/20 ,  A61K9/00 ,  A61K31/353 ,  A61K31/726 ,  A61K47/48 ,  A61K9/16 ,  A61K31/7032 ,  A61K31/7072 ,  A61K45/06

CPC classification number: A61K31/7056 ,  A61K9/0053 ,  A61K9/1635 ,  A61K9/1647 ,  A61K9/1652 ,  A61K9/167 ,  A61K9/20 ,  A61K31/198 ,  A61K31/353 ,  A61K31/7072 ,  A61K31/728 ,  A61K31/734 ,  A61K31/737 ,  A61K45/06 ,  A61K47/6937 ,  A61K2300/00

Abstract: A composition and associated method for treating a hepatitis C virus (HCV) infection in a subject who is human being. The composition includes: an anti-viral agent and/or a protease inhibitor; a polymerase inhibitor; one or more viral entry inhibitors; and one or more anti-fibrotic agents and/or anti-hemolytic agents including one or more Polyphenols and/or one or more Thiols. The composition may also include one or more sulfated oligosaccharide or non-anticoagulant glycosaminoglycans (GAGs). The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection.

Abstract translation: 用于治疗人类受试者的丙型肝炎病毒（HCV）感染的组合物和相关方法。 组合物包括：抗病毒剂和/或蛋白酶抑制剂; 聚合酶抑制剂; 一种或多种病毒进入抑制剂; 和一种或多种抗纤维化剂和/或抗溶血剂，包括一种或多种多酚和/或一种或多种硫醇。 组合物还可以包括一种或多种硫酸化寡糖或非抗凝血糖胺聚糖（GAG）。 该方法向受试者施用治疗剂量的组合物以治疗受试者HCV感染。

公开(公告)号：US09289395B2

公开(公告)日：2016-03-22

申请号：US12947389

申请日：2010-11-16

Applicant: Paul J. Davis ,  Shaker A. Mousa

Inventor： Paul J. Davis ,  Shaker A. Mousa

IPC: A61K9/14 ,  A61K9/51 ,  A61K31/192 ,  A61K47/48 ,  B82Y5/00

CPC classification number: A61K9/5153 ,  A61K31/192 ,  A61K47/593 ,  A61K47/595 ,  A61K47/60 ,  A61K47/61 ,  A61K47/6935 ,  A61K47/6937 ,  B82Y5/00

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的聚合物纳米颗粒形式的甲状腺激素激动剂，其部分激动剂或其拮抗剂，以促进或抑制受试者的血管生成。 还公开了甲状腺激素或甲状腺激素类似物的聚合形式的组合物。

公开(公告)号：US09272049B2

公开(公告)日：2016-03-01

申请号：US13156047

申请日：2011-06-08

Applicant: Maria Alexander-Bridges ,  Shaker A. Mousa ,  Paul J. Davis

Inventor： Maria Alexander-Bridges ,  Shaker A. Mousa ,  Paul J. Davis

IPC: A61K31/22 ,  A61K47/48

CPC classification number: G01N33/5023 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  C12N15/1086

Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.

Abstract translation: 本文提供了通过靶向选择的细胞外和细胞外蛋白质的RGD结合位点来预防和治疗与代谢综合征相关的疾病和危险因素的组合物和方法。 典型的组合物包括通过酯键的RGD-多酚共轭物; 与RGD类似物或模拟物缀合的多酚聚合物; 和与多酚连接的RGD聚合物缀合物。

公开(公告)号：US20150224134A1

公开(公告)日：2015-08-13

申请号：US14614496

申请日：2015-02-05

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/737 ,  A61K31/7072 ,  A61K31/728 ,  A61K31/198 ,  A61K31/734 ,  A61K31/7056 ,  A61K31/353

CPC classification number: A61K31/737 ,  A61K31/198 ,  A61K31/353 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/728 ,  A61K31/734 ,  A61K45/06 ,  A61K2300/00

Abstract: This disclosure concerns novel formulation and Nanoformulations as defined in the specification and compositions comprising combination of HCV protease and polymerase inhibitors, with or without interferon, along with anti-fibrotic/anti-hemolytic agents' combination of naturally driven Polyphenol/Thiols, and Non-anticoagulant GAGs. These compounds are effective antiviral agents, especially in inhibiting the function of the various genotypes of Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising nano-targeted delivery of novel nanoformulation containing combined composition for HCV and/or hepatic targeted delivery for improved efficacy and safety.

Abstract translation: 本公开涉及如本说明书中定义的新型制剂和纳米制剂，其包含具有或不具有干扰素的HCV蛋白酶和聚合酶抑制剂的组合以及天然驱动的多酚/硫醇与抗纤维化/抗溶血剂的组合的组合， 抗凝剂GAGs。 这些化合物是有效的抗病毒剂，特别是抑制丙型肝炎病毒（HCV）各种基因型的功能。 因此，本公开还涉及通过使用这些新化合物或包含纳米靶向递送含有用于HCV和/或肝靶向递送的组合组合物的新型纳米制剂的组合物来治疗HCV相关疾病或病症的方法，以提高功效和安全性。

公开(公告)号：US20150132399A1

公开(公告)日：2015-05-14

申请号：US14526660

申请日：2014-10-29

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/727 ,  A61K31/704 ,  A61K47/48

CPC classification number: A61K31/727 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K47/6935 ,  A61K47/6937

Abstract: A nanoformulation that includes nanoparticles. Each nanoparticle includes a shell in which a glycosaminoglycan (GAG is encapsulated. The GAG is ionically or covalently bonded to the shell. The GAG is selected from the group consisting of sulfated non-anticoagulant heparin (SNACH), super-sulfated non-anticoagulant heparin (S-SNACH), and a combination thereof. The shell includes Poly (lactic-co-glycolic acid) (PLGA), Polyethylene Glycol (PEG)-PLGA, maleimide-PEG-PLGA, chitosan, chitosan-PLGA, methoxy-polyethyleneglycol-poly (lactide-co-glycolide) (MPEG-PLGA)-(maleimide-PEG-PLGA), PLGA-Polycaprolate, or calcium alginate. A method of using the nanoformulation to treat a cancer in a subject includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the cancer.

Abstract translation: 包括纳米颗粒的纳米制剂。 每个纳米颗粒包括壳聚糖，其中糖胺聚糖（GAG被封装），GAG离子或共价键合到壳上，GAG选自硫酸化非抗凝血剂肝素（SNACH），超硫酸化非抗凝血剂肝素 （S-SNACH）及其组合，壳包括聚（乳酸 - 共 - 乙醇酸）（PLGA），聚乙二醇（PEG）-PLGA，马来酰亚胺-PEG-PLGA，壳聚糖，壳聚糖-PLGA，甲氧基 - 聚乙二醇 - 聚（丙交酯 - 共 - 乙交酯）（MPEG-PLGA） - （马来酰亚胺-PEG-PLGA），PLGA-聚己内酯或藻酸钙。使用纳米制剂治疗受试者的癌症的方法包括向患者施用 治疗有效量的用于治疗癌症的纳米制剂。

公开(公告)号：US08802240B2

公开(公告)日：2014-08-12

申请号：US13345194

申请日：2012-01-06

Applicant: Paul J. Davis ,  Shaker A. Mousa

Inventor： Paul J. Davis ,  Shaker A. Mousa

IPC: A61K31/198 ,  A61K31/192 ,  A61K31/704 ,  A61P29/00

CPC classification number: C07K16/2848 ,  A61K31/192 ,  A61K31/198 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K39/39533 ,  A61K45/06 ,  A61K2039/505 ,  B82Y5/00 ,  Y10T428/12729 ,  Y10T428/31815 ,  A61K2300/00

Abstract: Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.

Abstract translation: 公开了使用甲状腺激素类似物和/或其纳米颗粒或聚合物形式增加正常和/或化学抗性肿瘤或癌细胞的化学敏感性的方法。 还公开了使用甲状腺激素类似物和/或其纳米颗粒或聚合形式增加正常和/或放射抗性肿瘤或癌细胞的放射敏感性的方法。

公开(公告)号：US20110104283A1

公开(公告)日：2011-05-05

申请号：US12912826

申请日：2010-10-27

Applicant: Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed S. Ardawi

Inventor： Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed S. Ardawi

IPC: A61K38/46 ,  A61P19/00 ,  A61K9/14 ,  A61K33/32 ,  A61K33/06 ,  A61P19/10

CPC classification number: A61K36/31 ,  A61K9/5146 ,  A61K9/5161 ,  A61K31/593 ,  A61K33/06 ,  A61K33/32 ,  A61K38/4873 ,  A61K45/06 ,  C12Y304/22033 ,  A61K2300/00

Abstract: A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include Lepidium Sativum or other Lepidium extracts, calcium, vitamin D, and antioxidants. The method for treating a bone condition includes introducing the composition into the animal.

Abstract translation: 用于治疗动物骨骼状况的组合物和方法。 组合物包括活性成分的纳米制剂。 活性成分包括莴苣（Lepidium Sativum）或其他百日咳提取物，钙，维生素D和抗氧化剂。 用于治疗骨骼状况的方法包括将组合物引入动物体内。

公开(公告)号：US20110052715A1

公开(公告)日：2011-03-03

申请号：US12816287

申请日：2010-06-15

Applicant: Paul J. Davis ,  Faith B. Davis ,  Shaker A. Mousa ,  Gennadi V. Glinsky ,  Aleck Hercbergs

Inventor： Paul J. Davis ,  Faith B. Davis ,  Shaker A. Mousa ,  Gennadi V. Glinsky ,  Aleck Hercbergs

IPC: A61K9/14 ,  B32B5/00 ,  C07K14/575 ,  A61K31/74 ,  A61K38/22 ,  A61K38/18 ,  A61P5/14 ,  B82Y5/00

CPC classification number: A61K9/5031 ,  A61K31/192 ,  A61K41/0038 ,  A61K45/06 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  A61K47/64 ,  A61K47/643 ,  A61K47/645 ,  A61K47/6455 ,  A61K47/6937 ,  B82Y5/00 ,  Y10T428/2982

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的甲状腺激素激动剂，部分激动剂或其拮抗剂的聚合物纳米颗粒形式，以促进或抑制受试者的血管发生。 还公开了甲状腺激素或甲状腺激素类似物的纳米颗粒形式及其用途。

公开(公告)号：US09980933B2

公开(公告)日：2018-05-29

申请号：US13975725

申请日：2013-08-26

Applicant: Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

Inventor： Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

IPC: A61K47/48 ,  A61K31/198 ,  A61K31/192 ,  A61K31/195 ,  A61K45/06 ,  A61K38/18 ,  A61K9/14 ,  A61K47/60 ,  A61K47/58 ,  A61K47/61 ,  A61K9/00

CPC classification number: A61K31/198 ,  A61K9/00 ,  A61K9/146 ,  A61K31/192 ,  A61K31/195 ,  A61K38/1825 ,  A61K45/06 ,  A61K47/58 ,  A61K47/60 ,  A61K47/61 ,  A61K2300/00

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

公开(公告)号：US20170071873A1

公开(公告)日：2017-03-16

申请号：US15260967

申请日：2016-09-09

Applicant: Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed-Salleh M. Ardawi

Inventor： Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed-Salleh M. Ardawi

IPC: A61K31/01 ,  A61K9/51 ,  A61K9/19 ,  A61K9/50 ,  A61K47/48

CPC classification number: A61K31/01 ,  A61K9/1652 ,  A61K9/19 ,  A61K9/5031 ,  A61K9/5036 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K9/5161 ,  A61K31/353 ,  A61K47/59 ,  A61K47/6925

Abstract: A nano-composition and a method of using the composition. The composition includes nanoparticles. Each nanoparticle includes a shell encapsulating lycopene. The shell includes oligomerized (−)-epigallocatechin-3-O-gallate (OEGCG) electrostatically bonded to chitosan. The method of using the composition includes administering the nano-composition to a human being.

Abstract translation: 纳米组合物和使用该组合物的方法。 组合物包括纳米颗粒。 每个纳米颗粒包括封装番茄红素的壳。 外壳包含与壳聚糖静电键合的低聚（ - ） - 表没食子儿茶柚没有素（OEGCG）。 使用组合物的方法包括将纳米组合物给予人。